Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
Abolfazl Fateh 3 Articles
Low Levels of Extensively Drug-resistant Tuberculosis among Multidrug Resistant Tuberculosis Isolates and Their Relationship to Risk Factors: Surveillance in Tehran, Iran; 2006 to 2014
Alireza Hadizadeh Tasbiti, Shamsi Yari, Mostafa Ghanei, Mohammad Ali Shokrgozar, Abolfazl Fateh, Ahmadreza Bahrmand
Osong Public Health Res Perspect. 2017;8(2):116-123.   Published online April 30, 2017
DOI: https://doi.org/10.24171/j.phrp.2017.8.2.03
  • 2,477 View
  • 24 Download
  • 4 Citations
AbstractAbstract PDF
Objectives

Extensively drug-resistant tuberculosis (XDR-TB) is more expensive and difficult to treat than multidrug-resistant tuberculosis (MDR-TB), and outcomes for patients are much worse; therefore, it is important that clinicians understand the magnitude and distribution of XDR-TB. We conducted a retrospective study to compare the estimated incidence of and risk factors for M/XDR-TB with those of susceptible TB controls.

Methods

Sputum culture and drug susceptibility testing (DST) were performed in patients with known or suspected TB. Strains that were identified as MDR were subjected to DST for second-line drugs using the proportion method.

Results

Among 1,442 TB patients (mean age, 46.48 ± 21.24 years) who were culture-positive for Mycobacterium tuberculosis, 1,126 (78.1%) yielded isolates that were resistant to at least one first-line drug; there were 33 isolates (2.3%) of MDR-TB, of which three (0.2%) were classified as XDR-TB. Ofloxacin resistance was found in 10 (0.7%) isolates. Women were 15% more likely than men to yield M/XDR-TB isolates, but this difference was not significant. In a multivariate analysis comparing susceptible TB with X/MDR-TB, only one variable—the number of previous treatment regimens—was associated with MDR (odds ratio, 1.06; 95% confidence interval, 1.14–21.2).

Conclusion

The burden of M/XDR-TB cases is not sizeable in Iran. Nonetheless, strategies must be implemented to identify and cure patients with pre-XDR-TB before they develop XDR-TB. Our results provide a greater understanding of the evolution and spread of M/XDR-TB in an environment where drug-resistant TB has a low incidence.

Citations

Citations to this article as recorded by  
  • Mycobacterium tuberculosis PPE7 Enhances Intracellular Survival of Mycobacterium smegmatis and Manipulates Host Cell Cytokine Secretion Through Nuclear Factor Kappa B and Mitogen-Activated Protein Kinase Signaling
    Jing Suo, Xinyan Wang, Rongchuan Zhao, Pengjiao Ma, Liang Ge, Tao Luo
    Journal of Interferon & Cytokine Research.2022; 42(10): 525.     CrossRef
  • The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia
    Agumas Shibabaw, Baye Gelaw, Wondwossen Gebreyes, Richard Robinson, Shu-Hua Wang, Belay Tessema, Shampa Anupurba
    PLOS ONE.2020; 15(2): e0229040.     CrossRef
  • Spoligotype and Drug Susceptibility Profiles of Mycobacterium tuberculosis Complex Isolates in Golestan Province, North Iran


    Noormohamad Mansoori, Farzam Vaziri, Sirus Amini, Sharareh Khanipour, Shahin Pourazar Dizaji, Masoumeh Douraghi
    Infection and Drug Resistance.2020; Volume 13: 2073.     CrossRef
  • A comparative study of phenotypic and genotypic first- and second-line drug resistance testing of Mycobacterium tuberculosis
    Fatemeh Sakhaee, Morteza Ghazanfari, Nayereh Ebrahimzadeh, Farzam Vaziri, Fatemeh Rahimi Jamnani, Mehdi Davari, Safoora Gharibzadeh, Fatemeh Hemati Mandjin, Abolfazl Fateh, Seyed Davar Siadat
    Biologicals.2017; 49: 33.     CrossRef
Comparison of Three Different Methods for Detection of IL28 rs12979860 Polymorphisms as a Predictor of Treatment Outcome in Patients with Hepatitis C Virus
Abolfazl Fateh, Mohammadreza Aghasadeghi, Seyed D. Siadat, Farzam Vaziri, Farzin Sadeghi, Roohollah Fateh, Hossein Keyvani, Alireza H. Tasbiti, Shamsi Yari, Angila Ataei-Pirkooh, Seyed H. Monavari
Osong Public Health Res Perspect. 2016;7(2):83-89.   Published online April 30, 2016
DOI: https://doi.org/10.1016/j.phrp.2015.11.004
  • 2,184 View
  • 17 Download
  • 17 Citations
AbstractAbstract PDF
Objectives
This study aimed to evaluate the specificity, sensitivity, cost, and turn-around time of three methods of gene polymorphism analysis and to study the relationship between IL28B rs12979860 and SVR rate to pegIFN-α/RVB therapy among patients with chronic hepatitis C.
Methods
A total of 100 samples from chronic hepatitis C patients were analyzed in parallel using the three methods: direct sequencing, real-time polymerase chain reaction (PCR), amplification refractory mutation system (ARMS)-PCR.
Results
The different profiles for IL28B rs12979860 alleles (CC, CT, and TT) obtained with PCR-RFLP, ARMS-PCR, and direct sequencing were consistent among the three methods. Prevalence of rs12979860 genotypes CC, CT and TT in HCV genotype 1a was 10(19.6%), 35(68.6%), and six (11.8%), respectively, and in HCV genotype 31, it was 13(26.5%), 31(63.3%), and five (10.2%), respectively. No significant difference was seen between rs12979860 genotype and HCV genotype (p = 0.710).
Conclusion
Screening by ARMS – PCR SNOP detection represents the most efficient and reliable method to determine HCV polymorphisms in routine clinical practice.

Citations

Citations to this article as recorded by  
  • MicroRNAs Profiling in HIV, HCV, and HIV/HCV Co-Infected Patients
    Mohsen Moghoofei, Sohrab Najafipour, Shayan Mostafaei , Ahmad Tavakoli , Farah Bokharaei-Salim , Saied Ghorbani, Davod Javanmard, Hadi Ghaffari , Seyed Hamidreza Monavari
    Current HIV Research.2021; 19(1): 27.     CrossRef
  • Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms
    Amir Hossein Nafari, Ahmad Ayadi, Zahra Noormohamadi, Fatemeh Sakhaee, Farzam Vaziri, Seyed Davar Siadat, Abolfazl Fateh
    Infection, Genetics and Evolution.2020; 79: 104144.     CrossRef
  • Polymerase Chain Reaction Assay Using the Restriction Fragment Length Polymorphism Technique in the Detection of Prosthetic Joint Infections: A Multi-Centered Study
    Ataollah Moshirabadi, Mohammad Razi, Peyman Arasteh, Mohammad Mahdi Sarzaeem, Saman Ghaffari, Saied Aminiafshar, Kami Hosseinian Khosroshahy, Fatemeh Maryam Sheikholeslami
    The Journal of Arthroplasty.2019; 34(2): 359.     CrossRef
  • One-Step ARMS-PCR for the Detection of SNPs—Using the Example of the PADI4 Gene
    Ehnert, Linnemann, Braun, Botsch, Leibiger, Hemmann, Nussler
    Methods and Protocols.2019; 2(3): 63.     CrossRef
  • Epstein–Barr virus and risk of breast cancer: a systematic review and meta-analysis
    Mohammad Farahmand, Seyed Hamidreza Monavari, Zabihollah Shoja, Hadi Ghaffari, Mehdi Tavakoli, Ahmad Tavakoli
    Future Oncology.2019; 15(24): 2873.     CrossRef
  • Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography
    Eyal Shteyer, Louis Shekhtman, Tal Zinger, Sheri Harari, Inna Gafanovich, Dana Wolf, Hefziba Ivgi, Rima Barsuk, Ilana Dery, Daniela Armoni, Mila Rivkin, Rahul Pipalia, Michal Cohen Eliav, Yizhak Skorochod, Gabriel S. Breuer, Ran Tur-kaspa, Yonit Weil Wien
    PLOS ONE.2019; 14(1): e0210173.     CrossRef
  • Correlation of CD81 and SCARB1 polymorphisms on virological responses in Iranian patients with chronic hepatitis C virus genotype 1
    Milad Nafari, Shiva Irani, Farzam Vaziri, Safoora Gharibzadeh, Fatemeh Sakhaee, Mohammad Khazeni, Naser Kalhor, Fatemeh Rahimi Jamnani, Seyed Davar Siadat, Abolfazl Fateh
    Infection, Genetics and Evolution.2018; 62: 296.     CrossRef
  • First detection of human hepegivirus-1 (HHpgV-1) in Iranian patients with hemophilia
    Yazdan Bijvand, Mohammad Reza Aghasadeghi, Fatemeh Sakhaee, Parviz Pakzad, Farzam Vaziri, Alireza Azizi Saraji, Fatemeh Rahimi Jamnani, Seyed Davar Siadat, Abolfazl Fateh
    Scientific Reports.2018;[Epub]     CrossRef
  • Evaluation of TRIM5 and TRIM22 polymorphisms on treatment responses in Iranian patients with chronic hepatitis C virus infection
    Setareh Mobasheri, Nazanin Irani, Abbas Akhavan Sepahi, Fatemeh Sakhaee, Fatemeh Rahimi Jamnani, Farzam Vaziri, Seyed Davar Siadat, Abolfazl Fateh
    Gene.2018; 676: 95.     CrossRef
  • Data Mining and Machine Learning Algorithms Using IL28B Genotype and Biochemical Markers Best Predicted Advanced Liver Fibrosis in Chronic Hepatitis C
    Hend Ibrahim Shousha, Abubakr Hussein Awad, Dalia Abdelhamid Omran, Mayada Mohamed Elnegouly, Mahasen Mabrouk
    Japanese Journal of Infectious Diseases.2018; 71(1): 51.     CrossRef
  • IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C
    Parvaneh Sedighimehr, Shiva Irani, Fatemeh Sakhaee, Farzam Vaziri, Mohammadreza Aghasadeghi, Seyed Mehdi Sadat, Fatemeh Rahimi Jamnani, Abolfazl Fateh, Seyed Davar Siadat
    Archives of Virology.2017; 162(1): 181.     CrossRef
  • Comparison of Direct Sequencing, Real-Time PCR-High Resolution Melt (PCR-HRM) and PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) Analysis for Genotyping of Common Thiopurine Intolerant Variant Alleles NUDT15 c.415C>T and TPMT c.719A>G (TPMT*3C)
    Wai-Ying Fong, Chi-Chun Ho, Wing-Tat Poon
    Diagnostics.2017; 7(2): 27.     CrossRef
  • Effect of IL15 rs10833 and SCARB1 rs10846744 on virologic responses in chronic hepatitis C patients treated with pegylated interferon-α and ribavirin
    Sahar Sadeghi, Mehdi Davari, Esmaeil Asli, Safoora Gharibzadeh, Farzam Vaziri, Fatemeh Rahimi Jamnani, Abolfazl Fateh, Seyed Davar Siadat
    Gene.2017; 630: 28.     CrossRef
  • High platelet count and high probability of CALR detection in myeloproliferative neoplasms
    Reza Shirzad, Zari Tahan-nejad, Javad Mohamadi-asl, Mohammad Seghatoleslami, Ahmad Ahmadzadeh, Amal Saki Malehi, Najmaldin Saki
    Comparative Clinical Pathology.2017; 26(1): 25.     CrossRef
  • A comparative study of various methods for detection of IL28B rs12979860 in chronic hepatitis C
    Seyed Hamidreza Monavari, Roohollah Fateh, Farzam Vaziri, Fatemeh Rahimi Jamnani, Enayat Anvari, Farzin Sadeghi, Parviz Afrough, Ava Behrouzi, Fatemeh Sakhaee, Sepideh Meidaninikjeh, Hamidreza Mollaie, Alireza Hadizadeh Tasbiti, Shamsi Yari, Maryam Sadegh
    Scandinavian Journal of Clinical and Laboratory In.2017; 77(4): 247.     CrossRef
  • EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C
    M Asnavandi, M Zargar, F Vaziri, F R Jamnani, S Gharibzadeh, A Fateh, S D Siadat
    Genes & Immunity.2017; 18(3): 144.     CrossRef
  • Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection
    Farah Bokharaei-Salim, Mostafa Salehi-Vaziri, Farzin Sadeghi, Khadijeh Khanaliha, Maryam Esghaei, Seyed Hamidreza Monavari, Seyed Moayed Alavian, Shahin Fakhim, Hossein Keyvani
    Jundishapur Journal of Microbiology.2016;[Epub]     CrossRef
Preparation and Evaluation of a New Lipopolysaccharide-based Conjugate as a Vaccine Candidate for Brucellosis
Seyed Davar Siadat, Farzam Vaziri, Mamak Eftekhary, Maryam Karbasian, Arfa Moshiri, Mohammad R. Aghasadeghi, Mehdi S. Ardestani, Meghdad Abdollahpour Alitappeh, Amin Arsang, Abolfazl Fateh, Shahin Najar Peerayeh, Ahmad R. Bahrmand
Osong Public Health Res Perspect. 2015;6(1):9-13.   Published online February 28, 2015
DOI: https://doi.org/10.1016/j.phrp.2014.10.012
  • 2,185 View
  • 20 Download
  • 4 Citations
AbstractAbstract PDF
Objectives
Development of an efficacious vaccine against brucellosis has been a challenge for scientists for many years. At present, there is no licensed vaccine against human brucellosis. To overcome this problem, currently, antigenic determinants of Brucella cell wall such as Lipopolysaccharide (LPS) are considered as potential candidates to develop subunit vaccines.
Methods
In this study, Brucella abortus LPS was used for conjugation to Neisseria meningitidis serogroup B outer membrane vesicle (OMV) as carrier protein using carbodiimide and adipic acid–mediated coupling and linking, respectively. Groups of eight BALB/c mice were injected subcutaneously with 10 μg LPS alone, combined LPS + OMV and conjugated LPS–OMV on 0 days, 14 days, 28 days and 42 days. Anti-LPS IgG was measured in serum.
Results
The yield of LPS to OMV in LPS–OMV conjugate was 46.55%, on the basis of carbohydrate content. The ratio for LPS to OMV was 4.07. The LPS–OMV conjugate was the most immunogenic compound that stimulated following the first injection with increased IgG titer of ∼5-fold and ∼1.3-fold higher than that produced against LPS and LPS in noncovalent complex to OMV (LPS + OMV), respectively. The highest anti-LPS IgG titer was detected 2 weeks after the third injection (Day 42) of LPS–OMV conjugate. The conjugated compound elicited higher titers of IgG than LPS + OMV, that showed a 100–120-fold rise of anti-LPS IgG in mice.
Conclusion
These results indicate that our conjugated LPS–OMV can be used as a brucellosis vaccine, but further investigation is required.

Citations

Citations to this article as recorded by  
  • Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy
    Qiong Long, Peng Zheng, Xiao Zheng, Weiran Li, Liangqun Hua, Zhongqian Yang, Weiwei Huang, Yanbing Ma
    Advanced Drug Delivery Reviews.2022; 186: 114321.     CrossRef
  • Outer membrane vesicle vaccines
    Francesca Micoli, Calman A. MacLennan
    Seminars in Immunology.2020; 50: 101433.     CrossRef
  • Designing an immunosensor for detection of Brucella abortus based on coloured silica nanoparticles
    Arash Shams, Bahareh Rahimian Zarif, Mojtaba Salouti, Reza Shapouri, Sako Mirzaii
    Artificial Cells, Nanomedicine, and Biotechnology.2019; 47(1): 2562.     CrossRef
  • Bioengineering bacterial outer membrane vesicles as vaccine platform
    Matthias J.H. Gerritzen, Dirk E. Martens, René H. Wijffels, Leo van der Pol, Michiel Stork
    Biotechnology Advances.2017; 35(5): 565.     CrossRef

PHRP : Osong Public Health and Research Perspectives